Our scientific platform
Epigenetic modulation and HDACi
By harnessing epigenetic modulation, we aim to redefine how cardiovascular and pulmonary diseases are treated. Our HDAC-based approach targets fundamental regulatory pathways in disease biology, with the potential to deliver disease-modifying therapies where current options fall short.
Cereno Scientific’s pipeline
CS1 in PAH Phase II
CS1 is a well-tolerated oral therapy with a favorable safety profile and signals of disease-modifying effects as observed in a Phase IIa trial in patients with the rare disease pulmonary arterial hypertension (PAH).
CS1 aims to slow, halt and reverse PAH disease progression as a once-daily oral therapy. Unlike standard therapy that focus on managing symptoms, CS1 represents a novel therapeutic approach by targeting the root mechanisms of PAH. CS1 has ODD and a FDA Fast Track designation in PAH. Preparations are currently underway for a larger placebo-controlled Phase IIb trial with a planned trial initiation in Q2 2026.
CS014 in PH-ILD
CS014 is a new chemical entity and a HDAC inhibitor. Being an epigenetic modulator, CS014 has the potential to target the underlying pathophysiology of severe cardiopulmonary diseases with high unmet medical needs. In preclinical studies, CS014 has demonstrated strong effects on vascular remodeling, fibrosis and thrombosis, which are central to disease progression in several cardiovascular and pulmonary diseases. The Phase I trial met its primary endpoint, showing a favorable safety and tolerability profile. Preparations for a Phase II trial in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) with a planned trial initiation in Q1 2027.
CS585 in rare thrombotic disorders
CS585 is an oral, highly potent and selective prostacyclin (IP) receptor agonist that has demonstrated the potential to significantly improve disease mechanisms relevant to cardiovascular disease. Preclinical data indicates that it could potentially be used in indications like thrombosis prevention without increased risk of bleeding and pulmonary hypertension; rare diseases with high unmet medical needs are further being considered. A preclinical development program is currently ongoing.
Scientific publications
Explore scientific publications and abstracts that support and document the Company’s research and development.
Investor focus
Investors
We are committed to transparent communication and long-term value creation, providing investors with clear and timely information about the Company’s strategy, progress and performance.
Learn more
Patient focus
Patients
We are committed to developing treatments with patients at the center, aiming to improve lives and address areas of significant unmet medical need.
Learn more